Financial Results for FY 2024-25
Awaiting price reaction for this filing.
The Board approved audited standalone and consolidated results for FY25 on May 3, 2025. Standalone revenue from operations fell about 3% to ₹754.81 lakh (vs ₹778.12 lakh in FY24), but profit after tax rose roughly 18% to ₹88.94 lakh (vs ₹75.27 lakh), helped by lower material and finance costs; EPS improved to ₹0.89 from ₹0.75. On a consolidated basis, revenue declined about 3.5% to ₹981.29 lakh and PAT slipped to ₹189.67 lakh from ₹199.89 lakh. Operating cash flow stayed positive at ₹136.73 lakh. The auditor issued an unmodified opinion but flagged an Emphasis of Matter relating to the proposed amalgamation of Medinova into its holding company, Vijaya Diagnostic Centre Limited, effective April 1, 2024; shareholders approved the scheme on April 25, 2025 and NCLT approval is pending.
Negative standalone net worth (₹119.64 lakh) and the pending merger mean the equity is essentially a shell awaiting NCLT approval — shareholders will ultimately be looking at the swap ratio with Vijaya Diagnostic rather than standalone performance. Modest profit growth despite weaker top line is a positive operational signal but is unlikely to drive the stock until the amalgamation is cleared.